Assessment of the risk of complication in a patient suspected of having an infection, having a sofa score lower than two
AssigneeBiomerieux
InventorsMarie-Angélique CAZALIS, Karine KAISER, Alexandre PACHOT
Life of this patent
Estimating the term…
Abstract
A method for the in vitro or ex vivo assessment of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, including measuring the level of expression, in a biological sample obtained from said patient, of at least one expression product of the VEGFR2 gene.
Claims13
A method for the assessment, in vitro or ex vivo, of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, comprising measuring the level of expression of at least one expression product of the VEGFR2 gene in a biological sample obtained from the patient.
A kit for measuring, in vitro or ex vivo, the level of expression of at least one expression product of the VEGFR2 gene and of at least one expression product of the uPAR gene in a patient suspected of having an infection, having a SOFA score of less than two, comprising at least one specific binding partner for the at least one expression product of the VEGFR2 gene and at least one specific binding partner for the at least one expression product of the uPAR gene.
A kit for measuring, in vitro or ex vivo, the level of expression of at least one expression product of the VEGFR2 gene and of at least one expression product of the uPAR gene in a biological sample, comprising:
- specific tools or reagents enabling the quantities of the at least one expression product of the VEGFR2 gene and of the at least one expression product of the uPAR gene to be measured in the biological sample, and
- a control sample which is a sample calibrated to contain the quantities of the at least one expression product of the VEGFR2 gene and of the at least one expression product of the uPAR gene which correspond to known quantities of the at least one expression product of the VEGFR2 gene, and of the at least one expression product of the uPAR gene.
Dependencies are inferred from the claim text.